Ben Lamm of Colossal Biosciences and Anduril founder Palmer Luckey have launched a joint venture called Warhound. The goal is to produce military working dogs equipped with genetic editing, cloning and cybernetic hardware. The team says it plans to deliver its first dogs in 2027.

What happened?

The partnership between these two names is the truly interesting part of the story. Until now, Colossal had made headlines with its claims of "bringing back" extinct creatures like the mammoth and the dodo. Anduril, meanwhile, is a defense technology company that builds autonomous defense systems and works closely with the Pentagon. Warhound sits at the intersection of these two worlds: editing and replicating the genome of a living animal, then bolting hardware onto it.

Why does it matter?

The real issue here isn't technical innovation but the change in a technology's direction. Colossal's marketing story has for years been built around "conservation" and "saving species." The same toolkit — CRISPR-type gene editing, somatic cell cloning — is now being presented as the backbone of a military program. This is a familiar pattern in the defense sector: a capability first developed for civilian or scientific purposes turns dual-use in the search for funding and scale. There are plenty of examples, from GPS to drones.

Let's get more concrete. Military working dogs are nothing new; they've been used for decades in bomb detection, tracking and protection duties. Warhound's claim is to design this dog: tuning its endurance, olfactory sensitivity or stress tolerance at the genetic level, then standardizing a successful individual by cloning it. Cloned working dogs have technically been attempted before — commercial pet cloning in South Korea is the best-known example. But combining gene editing, cloning and implants in a single living system is a whole different level of complexity.

There's an important distinction here, too. Updating software is easy; reprogramming the biology of a mammal is not. Off-target mutations in gene editing, low success rates in cloning, and premature aging problems are all well documented. In other words, the promise of a "designer dog" harbors a large gap between laboratory conditions and reliability in the field.

Who does it affect, and how?

PartyPotential impact
Defense institutionsA standardized, replicable working animal — but unpredictable biological risk
Biotech sectorA shift from a "conservation" image to military funding, and a debate over reputation
RegulatorsNo clear rules for gene editing plus implants in a living animal
Animal welfareEthical and health problems in experimental creatures

The point that most needs discussing is the regulatory gap. Combining a gene-edited living animal with military equipment doesn't fit neatly into any existing weapons or animal welfare legislation. The concept of a "living weapon system" is legally undefined. When a drone crashes, it goes offline; a genetically modified living creature, on the other hand, can breed, escape and blend into the ecosystem. This is a category of risk that is very hard to undo.

What's next?

The 2027 delivery date is a promise that should be met with caution. In Colossal's past announcements, the distance between scientific reality and marketing language was frequently criticized; the studies behind the "we brought back the mammoth" headlines were often early-stage results. A military delivery timeline would have to pass stricter scrutiny than that. The first thing to watch will be a concrete prototype and independent verification.

Second, how the ethical and legal debate unfolds matters. Similar projects can slow down in the face of public backlash and institutional review. Third is the funding model: does this meet a real military need, or is it a shiny narrative for gaining access to the defense budget?

Ultimately, Warhound is less a technical breakthrough than a sign of a change in direction. The move of "species-saving" technology into the field of weaponization is real; but how much of the promised timeline and capability is concrete remains unclear. It's a venture for which one should expect evidence rather than scientific claims.